Ingrid Zhang - 15 Sep 2026 Form 4 Insider Report for Legend Biotech Corp (LEGN)

Reporting relationship: Chief Executive Officer
Issuer ticker: LEGN
Reported as of: 15 Sep 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 16 Sep 2026, 16:18:52 UTC
Prior SEC filing: 13 Nov 2025
Source filing: View source filing
Reporting owner signature: /s/ Robert Staloff, Attorney-in-Fact

Key filing fact

Ingrid Zhang filed Form 4 for Legend Biotech Corp (LEGN) on 16 Sep 2026.

Key facts

This page summarizes Ingrid Zhang's Form 4 filing for Legend Biotech Corp (LEGN).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 16 Sep 2026, 16:18.

Change

Previous filing in this sequence was filed on 13 Nov 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001964342 Primary reporting owner

Zhang Ingrid

Relationship: Chief Executive Officer
Address: C/O LEGEND BIOTECH CORP, 77 CORPORATE DRIVE, 4TH FLOOR, BRIDGEWATER
Signature: /s/ Robert Staloff, Attorney-in-Fact
Signature date: 16 Sep 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

LEGN transaction

Ordinary Shares

Award

Transaction value
Shares: +1,131,860
Change %
Price: $0.000000^*
Shares after: 1,131,860
Date: 15 Sep 2026
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents two ordinary shares of the Issuer.

Footnote F2

Represents restricted share units (the "RSUs"). Each RSU represents a contingent right to receive one ordinary share of the Issuer upon settlement. 1/3 of the RSUs vest and becomes exercisable on each of September 15, 2027, September 15, 2028, and September 15, 2029, respectively, subject to the Reporting Person's continued service to the Issuer on each such vesting date.